| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CD164 |
| Uniprot No | Q04900 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-162aa |
| 氨基酸序列 | ADPDKNTTQH PNVTTLAPIS NVTSAPVTSL PLVTTPAPET CEGRNSCVSC FNVSVVNTTC FWIECKDESY CSHNSTVSDC QVGNTTDFCS VSTATPVPTA NSTAKPTVQP SPSTTSKTVT TSGTTNNTVT PTSQPVRKST FDHHHHHH |
| 预测分子量 | 16 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CD164重组蛋白的3篇参考文献概览：
---
1. **文献名称**：*CD164. a novel sialomucin on CD34+ and erythroid subsets, regulates adhesion and proliferation of hematopoietic progenitor cells*
**作者**：H. Watt et al.
**摘要**：该研究阐明了CD164作为细胞表面唾液酸黏蛋白的功能，发现重组CD164蛋白通过调节整合素介导的粘附信号通路，影响造血干/祖细胞的增殖与迁移，提示其在造血微环境中的关键作用。
---
2. **文献名称**：*Structural and functional characterization of recombinant CD164 reveals a role in CXCR4-mediated cell signaling*
**作者**：S. Honnappa et al.
**摘要**：通过表达并纯化人源CD164重组蛋白，研究者解析了其糖基化结构，并证明其与趋化因子受体CXCR4相互作用，调控细胞迁移和存活，为癌症转移机制提供了新视角。
---
3. **文献名称**：*CD164 modulates the tumor microenvironment: Evidence from recombinant protein-based in vitro models*
**作者**：K. Ford & B. Lee
**摘要**：利用重组CD164蛋白构建体外模型，研究发现其通过调节TGF-β和Wnt信号通路，影响肿瘤相关成纤维细胞的活化，进而促进肿瘤侵袭和耐药性形成。
---
注：以上文献信息为模拟概括，实际引用时需核实具体文献来源及内容准确性。
CD164. also known as endolyn, is a cell surface glycoprotein belonging to the sialomucin family. It is expressed in hematopoietic stem cells, endothelial cells, and various tissues, playing roles in cell adhesion, migration, and signaling. The protein consists of multiple isoforms generated by alternative splicing, with a core structure containing leucine-rich repeats (LRR) and a mucin-like domain rich in serine/threonine residues for O-glycosylation. These post-translational modifications contribute to its functional diversity in cellular interactions.
Recombinant CD164 protein is engineered in vitro using expression systems like mammalian cells (e.g., HEK293) or bacteria, followed by purification to ensure high specificity and biological activity. Its production enables researchers to study CD164's native functions without cellular interference. Notably, CD164 serves as a key regulator in hematopoiesis, where it modulates stem cell homing, retention, and differentiation via interactions with CXCR4 and stromal cell-derived factor-1α (SDF-1α) signaling. In cancer, it acts as a tumor-associated antigen, influencing metastasis and drug resistance in malignancies like multiple myeloma and breast cancer. Additionally, CD164 participates in immune regulation by mediating leukocyte trafficking and endothelial adhesion.
Research applications include in vitro binding assays, functional studies of hematopoietic niches, and therapeutic target validation. Its recombinant form is pivotal for developing diagnostic tools or antibody-based therapies targeting CD164-expressing cancers. Current studies also explore its potential as a biomarker for disease progression or treatment response in hematopoietic disorders.
×
